Purpose: The role of sunitinib and sorafenib in the treatment of metastatic renal cell carcinoma (mRCC) is reviewed. Conclusion: The tyrosine kinase inhibitors sorafenib and sunitinib offer ...

There are conflicting data regarding the effects of TK inhibitors on tumor immunity ... The study of imatinib and sorafenib would be insufficient to conclude an overall estimation.

The trial compared the combo against the investigator's choice of tyrosine kinase inhibitor monotherapy - either lenvatinib ...

During a live event, Richard F. Riedel, MD, discussed key efficacy and safety outcomes from the phase 3 DeFi trial in ...

Tolebrutinib is an oral, brain-penetrant, and bioactive Bruton’s tyrosine kinase inhibitor that modulates peripheral ...

Chronic pain, a common and debilitating condition, often leads practitioners to prescribe opioids in escalating doses.

Bristol-Myers Squibb has claimed its second FDA approval in the space of a few days for its immuno-oncology combination of ...

Approval of Opdivo plus Yervoy combination was based on results from the Phase III CheckMate-9DW trial, which demonstrated ...

Although we predict that protein tyrosine kinase inhibitors such as the second generation inhibitors nilotinib and dasatinib will significantly inhibit the progression of disease in patients with ...

The U.S. Food and Drug Administration (FDA) has granted full approval to Vitrakvi (larotrectinib) for the treatment of adult ...

A Cleveland Clinic-led clinical trial of tolebrutinib, an investigational oral Bruton's tyrosine kinase inhibitor, a group of drugs originally developed to treat lymphomas and related blood disorders, ...